secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123289
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025
--------------------------------------------------------------------------------

- Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.
- Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.
- FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.
- FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.
- Preclinical programs advancing toward development candidate selection in HD and DM1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/0000950170-24-123289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024123289/dsgn-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer